When was Nykode Therapeutics founded?

Nykode Therapeutics was founded in 2006 and raised its 1st funding round 6 years after it was founded.

Where is Nykode Therapeutics located?

Nykode Therapeutics is headquartered in Oslo, Norway. It is registered at Gaustadalléen 21, 0349, OSLO.

Who is the current CEO of Nykode Therapeutics?

Michael Engsig of Nykode Therapeutics.

How many employees does Nykode Therapeutics have?

As of Aug 31, 2026, the latest employee count at Nykode Therapeutics is 76.

Is Nykode Therapeutics a funded company?

Nykode Therapeutics is a funded company, having raised a total of $961K across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Nov 12, 2012.

When was the latest funding round of Nykode Therapeutics?

Nykode Therapeutics' latest funding was a $***** Grant (prize money) round on Mar 01, 2015, with participation from 1 investor.

What is the annual revenue of Nykode Therapeutics?

Annual revenue of Nykode Therapeutics is less than $1M as on Dec 31, 2024

Where does Nykode Therapeutics rank among its competitors?

Nykode Therapeutics ranks 1173rd amongst 3571 active competitors, of which 1193 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Nykode Therapeutics?

Nykode Therapeutics' top competitors include Jazz Pharmaceuticals, X4 Pharmaceuticals and Sana Biotechnology. Among them, Immuneel secured the most recent funding round in June, 2026.

Nykode Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Nykode Therapeutics is a public company based in Oslo (Norway), founded in 2006 by Agnete Fredriksen. It operates as a Developer of vaccines and immunotherapeutics for cancer and infectious diseases. Nykode Therapeutics has raised $961K in funding. The company has 3571 active competitors, including 1193 funded and 847 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, X4 Pharmaceuticals and Sana Biotechnology.

Company Details

Developer of vaccines and immunotherapeutics for cancer and infectious diseases. The product line include VB10.16, a therapeutic vaccine for the treatment of human papillomavirus-induced cervical cancer, and VB10.NEO is an individualized cancer neoantigen vaccine for metastatic tumors. It has Vaccibody modular immunotherapy technology platform designed for precision targeting and enabling tailored activation of antigen-presenting cells to optimize immune engagement.

Website: nykode.com
Email ID: *****@nykode.com
Phone Number: +47 **********
Registered Address: Gaustadalléen 21, 0349, OSLO

Key Metrics

Founded Year

2006

Location

Oslo, Norway

Stage

Public

Total Funding

$961K in 3 rounds

Latest Funding Round

Grant (prize money), Mar 01, 2015, $*****

Investors

TD Veen & 5 more

Ranked

1173^rd among 3571 active competitors

Annual Revenue

$0 - $1M as on Dec 31, 2024

Employee Count

76 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3384 more

Exit Details

Public

View Nykode Therapeutics' full profile

Nykode Therapeutics is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count
Nykode Therapeutics Asa CIN: 990646066 , Norway, Active	Nov 21, 2006	$0 - $1M (As on Dec 31, 2024)	167 (As on Dec 31, 2024)
Nykode Therapeutics Denmark A/S CIN: 42038660 , Denmark, Active	Jul 31, 2021	-	36 (As on Mar 31, 2024)
Nykode Therapeutics AS CIN: 990646066 , Norway, Active		-	102 (As on Dec 31, 2021)

Nykode Therapeutics got listed on Jun 16, 2022.

Click here to take a look at Nykode Therapeutics's IPO in detail

Nykode Therapeutics has raised a total funding of $961K over 3 rounds. Its first funding round was on Nov 12, 2012. Its latest funding round was a Grant (prize money) round on Mar 01, 2015 for $*****. 1 investor participated in its latest round. Nykode Therapeutics has 6 institutional investors.

Here is the list of recent funding rounds of Nykode Therapeutics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 01, 2015	9200511	Grant (prize money)	8655866	1587663	4878619	4329654
Jun 26, 2013	8518568	Seed	5134740	4631593	7394780	2532153
Nov 12, 2012	3491223	Grant (prize money)	4471612	3249439	8319450	8777531

Access funding benchmarks and valuations. Sign up today!

View details of Nykode Therapeutics's funding rounds and investors

The founders of Nykode Therapeutics is Agnete Fredriksen. Michael Engsig is the CEO of Nykode Therapeutics.

Here are the details of Nykode Therapeutics' key team members:

Agnete Fredriksen: Co-Founder & Chief Business Officer of Nykode Therapeutics.
Michael Engsig: CEO of Nykode Therapeutics.
Contact Info: 1 email address

Nykode Therapeutics' Board of Directors

Nykode Therapeutics's board has 3 active members. Michael Thyrring Engsig is part of team and Christian Åbyholm and Trygve Lauvdal are independent board members.

Here is the list of Nykode Therapeutics' board of directors:

Name	Type	Representing	Status	Duration
Michael Thyrring Engsig	Team	-	Current	-
Christian Åbyholm	Independent board member	-	Current	-
viop{mj	Independent board member	-	Current	2y 8m

View details of Nykode Therapeutics's Founder profiles and Board Members

Nykode Therapeutics' employee count trend

Nykode Therapeutics has 76 employees as of Aug 26. Here is Nykode Therapeutics's employee count trend over the years:

Employee count trend for Nykode Therapeutics

Uncover Nykode Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Nykode Therapeutics include Jazz Pharmaceuticals, X4 Pharmaceuticals and Sana Biotechnology. Here is the list of Top 10 competitors of Nykode Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	X4 Pharmaceuticals 2014, Boston (United States), Public	Developer of small molecule drugs for the treatment of cancer	$58.2M	Coastlands Capital, BVF Partners & 20 others	76/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
1173rd	Nykode Therapeutics 2006, Oslo (Norway), Public	Developer of vaccines and immunotherapeutics for cancer and infectious diseases	$961K	TD Veen, Radforsk & 4 others	40/100